The AP3D1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited population of the human A-549 lung carcinoma line with targeted disruption of the AP3D1 gene. This polyclonal knockout pool provides a heterogeneous model for studying AP-3 delta subunit function in vesicular trafficking and cargo sorting. Cells harbor a diverse array of indel mutations that collectively ablate protein expression, avoiding clonal artifacts. The format is suitable for high-throughput screening and population-level phenotypic analyses. Supplied as a viable stock, these cells are ready for immediate functional genomic applications.
A-549 is an alveolar basal epithelial adenocarcinoma line from a 58-year-old male. The adherent cells exhibit a hypotriploid karyotype with a modal chromosome number of 66 and are extensively used in cancer biology, pharmacology, and respiratory research. Their active endocytic pathways and retention of pneumocyte features make them an optimal host for trafficking studies. Genetic manipulation of A-549 cells allows dissection of molecular processes within a lung adenocarcinoma context.
The AP3D1 gene product is the delta subunit of the heterotetrameric adaptor protein complex AP-3, which functions in clathrin-dependent vesicle trafficking from the trans-Golgi network to lysosomes and melanosomes. The complex, comprising also beta3 (AP3B1), mu3 (AP3M1), and sigma3 (AP3S1) subunits, is activated by ARF1 and RAB GTPases and interfaces with the BLOC-1 complex. It recognizes tyrosine-based sorting signals on cargoes such as LAMP1, CD63, TYRP1, and VAMP7. Disruption of AP3D1 abolishes AP-3 holocomplex assembly, leading to missorting of these cargoes and impaired lysosomal biogenesis, melanosome maturation, and endolysosomal homeostasis.
In A-549 cells, endolysosomal trafficking governs key cancer-related processes including cell migration, invasion, and response to chemotherapeutic agents. AP3D1 disruption perturbs lysosomal enzyme delivery and surface receptor recycling, which may alter the degradative capacity and signaling dynamics of these cells. Defects in AP-3 function are directly linked to Hermansky-Pudlak syndrome type 9, a genetic disorder characterized by oculocutaneous albinism and platelet storage pool deficiency, underscoring the translational relevance of this model. Additionally, the role of AP-3 in sorting metalloproteases and adhesion molecules places AP3D1 within pathways that modulate extracellular matrix remodeling and metastatic potential. Thus, this A-549 knockout pool provides a unique tool to dissect the intersection of intracellular trafficking and oncogenic phenotypes in a well-characterized carcinoma background.
This polyclonal knockout pool is ideally suited for functional genomic screens and mechanistic investigations. Users can assess lysosomal integrity and cargo distribution via immunofluorescence and flow cytometry targeting LAMP1 and CD63, measure lysosomal enzyme activity, and perform clathrin-mediated endocytosis assays with transferrin or EGF. Co-immunoprecipitation of AP-3 subunits confirms complex disruption. In an A-549 context, migration assays and drug sensitivity profiling explore the intersection of trafficking and cancer phenotypes. For additional support and product details, please contact Ascent Research.
